Krátká Karolína, Havrda Martin, Honsová Eva, Rychlík Ivan
1st Department of Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Clinical and Transplant Pathology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Case Rep Nephrol Dial. 2018 Oct 2;8(3):216-222. doi: 10.1159/000493093. eCollection 2018 Sep-Dec.
Anticoagulation-related nephropathy (ARN) is a significant and underdiagnosed complication in patients who receive anticoagulation therapy. It is characterized by acute kidney injury in the setting of excessive anticoagulation defined as an international normalized ratio > 3.0 in patients treated with warfarin. A definitive diagnosis is made by renal biopsy showing acute tubular necrosis with obstruction of the tubuli by red blood cell casts. However, the evidence shows that ARN can occur during treatment with novel oral anticoagulants as well. Although it has been suggested that antiplatelet therapy, such as aspirin, might contribute to coagulopathy (and therefore the hypothetical risk of ARN), there are no reports of ARN induced by antiplatelet therapy according to our knowledge. It is also reported that glomerular lesions (i.e., kidney disease) represent a risk factor for ARN. We present a case of an 82-year-old man who developed biopsy-proven ARN after the administration of dual antiplatelet therapy with no previous anticoagulation treatment and normal coagulation tests.
抗凝相关肾病(ARN)是接受抗凝治疗患者中一种严重且诊断不足的并发症。其特征为在过度抗凝情况下出现急性肾损伤,对于接受华法林治疗的患者,过度抗凝定义为国际标准化比值>3.0。通过肾活检显示急性肾小管坏死且肾小管被红细胞管型阻塞来做出明确诊断。然而,有证据表明ARN也可在使用新型口服抗凝剂治疗期间发生。尽管有人提出抗血小板治疗(如阿司匹林)可能导致凝血病(进而存在ARN的潜在风险),但据我们所知,尚无抗血小板治疗诱发ARN的报道。也有报道称肾小球病变(即肾脏疾病)是ARN的一个危险因素。我们报告一例82岁男性患者,在接受双联抗血小板治疗后出现经活检证实的ARN,该患者既往未接受抗凝治疗且凝血试验正常。